|
1
|
Barwick BG, Gupta VA, Vertino PM and Boise
LH: Cell of origin and genetic alterations in the pathogenesis of
multiple myeloma. Front Immunol. 10:11212019. View Article : Google Scholar
|
|
2
|
Kyle RA and Rajkumar SV: Multiple myeloma.
Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shah N, Aiello J, Avigan DE, Berdeja JG,
Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, et
al: The society for immunotherapy of cancer consensus statement on
immunotherapy for the treatment of multiple myeloma. J Immunother
Cancer. 8:e0007342020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rajkumar SV: Multiple myeloma: 2018 update
on diagnosis, risk-stratification, and management. Am J Hematol.
93:981–1114. 2018. View Article : Google Scholar
|
|
5
|
Dingli D, Ailawadhi S, Bergsagel PL, Buadi
FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR,
Kapoor P, et al: Therapy for relapsed multiple myeloma: Guidelines
from the mayo stratification for myeloma and risk-adapted therapy.
Mayo Clin Proc. 92:578–598. 2017. View Article : Google Scholar
|
|
6
|
Scott K, Hayden PJ, Will A, Wheatley K and
Coyne I: Bortezomib for the treatment of multiple myeloma. Cochrane
Database Syst Rev. 4:CD0108162016.PubMed/NCBI
|
|
7
|
Tibullo D, Giallongo C, Romano A, Vicario
N, Barbato A, Puglisi F, Parenti R, Amorini AM, Wissam Saab M,
Tavazzi B, et al: Mitochondrial functions, energy metabolism and
protein glycosylation are interconnected processes mediating
resistance to bortezomib in multiple myeloma cells. Biomolecules.
10:6962020. View Article : Google Scholar
|
|
8
|
Zaal EA, Wu W, Jansen G, Zweegman S, Cloos
J and Berkers CR: Bortezomib resistance in multiple myeloma is
associated with increased serine synthesis. Cancer Metab. 5:72017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Robak P, Drozdz I, Szemraj J and Robak T:
Drug resistance in multiple myeloma. Cancer Treat Rev. 70:199–208.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spaan I, Raymakers RA, van de Stolpe A and
Peperzak V: Wnt signaling in multiple myeloma: A central player in
disease with therapeutic potential. J Hematol Oncol. 11:672018.
View Article : Google Scholar
|
|
11
|
Pai SG, Carneiro BA, Mota JM, Costa R,
Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK and Giles FJ:
Wnt/beta-catenin pathway: Modulating anticancer immune response. J
Hematol Oncol. 10:1012017. View Article : Google Scholar
|
|
12
|
Grigson ER, Ozerova M, Pisklakova A, Liu
H, Sullivan DM and Nefedova Y: Canonical Wnt pathway inhibitor
ICG-001 induces cytotoxicity of multiple myeloma cells in
Wnt-independent manner. PLoS One. 10:e01176932015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu F, Zhu Y, Lu Y, Yu Z, Zhong J, Li Y and
Pan J: Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and
induces apoptosis in multiple myeloma cells. Oncol Lett.
15:5871–5878. 2018.
|
|
14
|
Harada Y, Ishii I, Hatake K and Kasahara
T: Pyrvinium pamoate inhibits proliferation of
myeloma/erythroleukemia cells by suppressing mitochondrial
respiratory complex I and STAT3. Cancer Lett. 319:83–88. 2012.
View Article : Google Scholar
|
|
15
|
Hirakawa T, Nasu K, Miyabe S, Kouji H,
Katoh A, Uemura N and Narahara H: β-catenin signaling inhibitors
ICG-001 and C-82 improve fibrosis in preclinical models of
endometriosis. Sci Rep. 9:200562019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salem K, Brown CO, Schibler J and Goel A:
Combination chemotherapy increases cytotoxicity of multiple myeloma
cells by modification of nuclear factor (NF)-κB activity. Exp
Hematol. 41:209–218. 2013. View Article : Google Scholar
|
|
17
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thibaudeau TA and Smith DM: A practical
review of proteasome pharmacology. Pharmacol Rev. 71:170–197. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Terpos E, Kleber M, Engelhardt M, Zweegman
S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A,
et al: European myeloma network guidelines for the management of
multiple myeloma-related complications. Haematologica.
100:1254–1266. 2015. View Article : Google Scholar
|
|
20
|
Dai Y, Guo X and Yang C: Effect of
bortezomib on proliferation and apoptosis of myeloma cells by
activating Wnt/β-catenin signaling pathway. Oncol Lett.
20:1295–1299. 2020. View Article : Google Scholar
|
|
21
|
Guo N and Peng Z: MG132, a proteasome
inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol.
9:6–11. 2013. View Article : Google Scholar
|
|
22
|
Harousseau JL, Attal M, Avet-Loiseau H,
Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus
P, et al: Bortezomib plus dexamethasone is superior to vincristine
plus doxorubicin plus dexamethasone as induction treatment prior to
autologous stem-cell transplantation in newly diagnosed multiple
myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol.
28:4621–4629. 2010. View Article : Google Scholar
|
|
23
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar
|
|
24
|
Taciak B, Pruszynska I, Kiraga L, Bialasek
M and Krol M: Wnt signaling pathway in development and cancer. J
Physiol Pharmacol. 69:2018.
|
|
25
|
Shi J, Liu Y, Xu X, Zhang W, Yu T, Jia J
and Liu C: Deubiquitinase USP47/UBP64E regulates beta-Catenin
ubiquitination and degradation and plays a positive role in Wnt
signaling. Mol Cell Biol. 35:3301–3311. 2015. View Article : Google Scholar
|
|
26
|
Peterson LF, Sun H, Liu Y, Potu H,
Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun D, et
al: Targeting deubiquitinase activity with a novel small-molecule
inhibitor as therapy for B-cell malignancies. Blood. 125:3588–3597.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su N, Wang P and Li Y: Role of
Wnt/beta-catenin pathway in inducing autophagy and apoptosis in
multiple myeloma cells. Oncol Lett. 12:4623–4629. 2016. View Article : Google Scholar
|
|
28
|
Bjorklund CC, Ma W, Wang ZQ, Davis RE,
Kuhn DJ, Kornblau SM, Wang M, Shah JJ and Orlowski RZ: Evidence of
a role for activation of Wnt/beta-catenin signaling in the
resistance of plasma cells to lenalidomide. J Biol Chem.
286:11009–11020. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu Y, Chen H, Zheng P, Zheng Y, Luo Q,
Xie G, Ma Y and Shen L: ICG-001 suppresses growth of gastric cancer
cells and reduces chemoresistance of cancer stem cell-like
population. J Exp Clin Cancer Res. 36:1252017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chan KC, Chan LS, Ip JC, Lo C, Yip TT,
Ngan RK, Wong RN, Lo KW, Ng WT, Lee AW, et al: Therapeutic
targeting of CBP/β-catenin signaling reduces cancer stem-like
population and synergistically suppresses growth of EBV-positive
nasopharyngeal carcinoma cells with cisplatin. Sci Rep. 5:99792015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Won HS, Lee KM, Oh JE, Nam EM and Lee KE:
Inhibition of β-Catenin to overcome endocrine resistance in
tamoxifen-resistant breast cancer cell line. PLoS One.
11:e01559832016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao Y, Masiello D, McMillian M, Nguyen C,
Wu Y, Melendez E, Smbatyan G, Kida A, He Y, Teo JL and Kahn M:
CBP/catenin antagonist safely eliminates drug-resistant
leukemia-initiating cells. Oncogene. 35:3705–3717. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang C, Zhang Z, Zhang S, Wang W and Hu
P: Targeting of Wnt/β-Catenin by anthelmintic drug pyrvinium
enhances sensitivity of ovarian cancer cells to chemotherapy. Med
Sci Monit. 23:266–275. 2017. View Article : Google Scholar
|
|
34
|
Cui L, Zhao J and Liu J: Pyrvinium
sensitizes clear cell renal cell carcinoma response to chemotherapy
via Casein Kinase 1alpha-dependent inhibition of Wnt/β-Catenin. Am
J Med Sci. 355:274–280. 2018. View Article : Google Scholar
|
|
35
|
Feng J, Jiang W, Liu Y, Huang W, Hu K, Li
K, Chen J, Ma C, Sun Z and Pang X: Blocking STAT3 by pyrvinium
pamoate causes metabolic lethality in KRAS-mutant lung cancer.
Biochem Pharmacol. 177:1139602020. View Article : Google Scholar
|
|
36
|
Dattilo R, Mottini C, Camera E, Lamolinara
A, Auslander N, Doglioni G, Muscolini M, Tang W, Planque M,
Ercolani C, et al: Pyrvinium pamoate induces death of
triple-negative breast cancer stem-like cells and reduces
metastases through effects on lipid anabolism. Cancer Res.
80:4087–4102. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu DH, Macdonald J, Liu G, Lee AS, Ly M,
Davis T, Ke N, Zhou D, Wong-Staal F and Li QX: Pyrvinium targets
the unfolded protein response to hypoglycemia and its anti-tumor
activity is enhanced by combination therapy. PLoS One. 3:e39512008.
View Article : Google Scholar : PubMed/NCBI
|
